Unresolved issues in the use of check-point inhibitors in NSCLC

F. Shepherd (Toronto, Canada)

Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Number: 3
Disease area: Thoracic oncology

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Shepherd (Toronto, Canada). Unresolved issues in the use of check-point inhibitors in NSCLC. ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: